IMMP Immutep

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Media Release

SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.

Presentation Details:

Date:        Wednesday, 7 December 2022                 

Time:        11:20am EST                 

Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available and after the meeting within the Investors & Media section of Immutep’s website.

About Immutep

Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (917) 679 9282; 



EN
02/12/2022

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Positive Update from Phase I Study of IMP761, a Firs...

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesSingle ascending dose levels will continue with 2.5, 7 and 14 mg/kgAdditional data from the Phase I to follow in second half of CY2025  SYDNEY, AUSTRALIA, June 23, 2025 ...

June 23, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Pri...

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation at a future medical meeting  SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiate...

May 27, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves ...

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS

May 15, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q3 FY25

Immutep Quarterly Activities Report Q3 FY25 Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcomaPatient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLCStrong cash position of A$146.25 mil...

April 29, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep to Participate in Upcoming Investor Conferences

Immutep to Participate in Upcoming Investor Conferences SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --   (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:   Jones Healthcare and Technology Innovation Conference Location:Las Vegas, NV Date:        Wednesday, 9 April 2025 Time:4:30 pm ET    The Citizens Life Sciences ConferenceLocation:New York, NYDate:Thursday, 8 May 2025Time:1:00 ...

April 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch